AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read$ISRG

Intuitive Surgical 3Q 2026: Revenue $3.05B, EPS $1.49— 10-Q Summary

Intuitive Surgical reported Q3 2026 revenue of $3.05B, up 22% YoY, but net income fell 25.8% to $522.8M. EPS was $1.49, down 23.6% YoY. Growth was driven by instruments, accessories, and systems sales. The da Vinci installed base grew 12% to 12,094 systems, and the Ion platform saw a 21% increase in installations.

Original reporting
tradingview.com
Published Oct 21, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Intuitive Surgical 3Q 2026: Revenue $3.05B, EPS $1.49— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$ISRGBearishMed
01

Why it matters

The earnings release provides fresh data for traders to reassess valuation and margin outlook.

02

Market read

First‑report earnings for a major med‑tech player, offering new pricing and margin data.

03

What to watch

Leasing mix and tariff refunds boosted margins; future lease revenue may improve profitability.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Intuitive Surgical filed its Q3 2026 10‑Q, highlighting strong sales of da Vinci systems and accessories.

Company-level read

Ticker impact

$ISRGBearishHigh confidence
Context

Intuitive Surgical reported Q3 2026 revenue of $3.05B (+22% YoY) and diluted EPS of $1.49, a 23.6% decline from the prior year.

Expected impact

likely downside pressure as the market prices in the earnings miss

Evidence & confidence

Revenue beat but EPS fell sharply, suggesting margin compression; investors typically react negatively to profit declines.

Market effects

Sector

Healthcare robotics may see mixed sentiment as revenue growth is strong but profitability concerns arise.

Regional

U.S. healthcare equipment sector could experience modest pullback.

Global

Limited; impact confined mainly to U.S. and global med‑tech investors.

Counterpoint

What could challenge this read

The revenue surge could signal a longer‑term growth runway, outweighing short‑term EPS miss.

Key entities

  • company
    Intuitive Surgical

    Manufacturer of da Vinci surgical robots.

Read at source← All news

StoryIntuitive Surgical posts Q3 2026 earnings beat, settles antitrust case and narrows procedure‑growth outlook

Also covered by

4 outlets

Related articles

OCT 23
$ISRGMedAI 8/10

Intuitive Surgical Sinks 6% as U.S. da Vinci Growth Slows to “Lowest We’ve Seen Since COVID”

Intuitive Surgical (ISRG) shares dropped 6% after reporting Q3 revenue of $3.05B, adjusted EPS of $3.00, and U.S. da Vinci procedure growth of 10%, the lowest since COVID. The company narrowed its 2026 procedure growth outlook and took a $450M antitrust charge. Management plans to cut instrument and accessory revenue per procedure by 3%-5% to boost volume.

finance.yahoo.com3 min
OCT 21
$ISRGMedAI 8/10

Intuitive’s US da Vinci procedure growth slows again

Intuitive Surgical reported Q3 revenue of $3.05B, up 22% YoY, with net income of $523M. U.S. da Vinci procedure growth slowed to 10%, the lowest since the pandemic. CEO David Rosa cited adoption challenges in benign general surgery. The company cut instrument prices to boost adoption in high-volume procedures, reducing near-term revenue per procedure. Intuitive adjusted its 2026 da Vinci procedure growth forecast to 14-15%.

finance.yahoo.com2 min